Healio

Implantable 1-year CGM sensor can ‘effectively manage’ type 1 or type 2 diabetes

Adults with diabetes using an implantable 1-year continuous glucose monitoring sensor had a mean time in range of about 66% ...
Nasdaq

GLUCOTRACK ANNOUNCES PRECLINICAL TESTING WITH IMPLANTABLE CONTINUOUS GLUCOSE MONITOR

Rutherford, NJ, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with ...
Nasdaq

Senseonics Announces the First Patient Implant of the Eversense E3 CGM System in the U.S.

GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous ...
Healio

Fully-implantable CGM receives FDA authorization for integration with insulin pumps

Please provide your email address to receive an email when new articles are posted on . The FDA granted marketing approval to allow the Eversense E3 CGM to be integrated with insulin delivery systems.
Business Wire

Eversense 365 Receives FDA Clearance: The World’s First One Year CGM

With a single sensor, the Eversense 365 system provides one year of use, versus 10-14 days with short-term CGM’s for minimal life disruption GERMANTOWN, Md. & PARSIPPANY, N.J.--(BUSINESS ...
Seeking Alpha

Senseonics Receives European Approval for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor

GERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous ...
FierceBiotech

GlucoTrack’s 2-year implantable CGM boasts high accuracy in early tests, paving the way for human trials

Last summer, GlucoTrack reported preliminary results from a feasibility study of its implantable continuous glucose monitor technology indicating that the sensor could indeed remain safely implanted ...
MobiHealthNews

GluSense gets funding for implantable biosensor it says could be a year-long CGM

GluSense, an Israeli medical device company, announced an undisclosed investment from the JDRF T1D Fund, a recently launched VC philanthropy fund dedicated to funding early stage programs for Type 1 ...
Seeking Alpha

Eversense 365 Receives FDA Clearance: The World’s First One Year CGM

GERMANTOWN, Md. and PARSIPPANY, N.J., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (SENS), a medical technology company focused on the development and manufacturing of long-term, ...